182 related articles for article (PubMed ID: 31645345)
1. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
[TBL] [Abstract][Full Text] [Related]
2. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.
Zhang L; Chen Y; Lv Y; Jiao S; Zhao W
Oncologist; 2022 Apr; 27(4):245-250. PubMed ID: 35380719
[TBL] [Abstract][Full Text] [Related]
4. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
6. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
[TBL] [Abstract][Full Text] [Related]
7. Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: a case report.
Şahin EA; Taşkıran EZ; Kiper PÖŞ; Aydın B; Utine E
J Med Case Rep; 2022 Jul; 16(1):306. PubMed ID: 35902966
[TBL] [Abstract][Full Text] [Related]
8. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD
Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920
[No Abstract] [Full Text] [Related]
9. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
10. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
11. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
[No Abstract] [Full Text] [Related]
12. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
13. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.
Hennemann A; Collonge Rame MA; Puzenat E; Ged C; Harbon S; Aubin F; Nardin C
Acta Oncol; 2022 Sep; 61(9):1140-1142. PubMed ID: 35950634
[No Abstract] [Full Text] [Related]
17. Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.
Yang Y; Jain RK; Glenn ST; Xu B; Singh PK; Wei L; Hu Q; Long M; Hutson N; Wang J; Battaglia S; George S
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221012
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K; Masetti M; Pfarr N; Lorenzen S
Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
20. Performance Characteristics of Mutational Signature Analysis in Targeted Panel Sequencing.
Lawrence L; Kunder CA; Fung E; Stehr H; Zehnder J
Arch Pathol Lab Med; 2021 Nov; 145(11):1424-1431. PubMed ID: 33571361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]